Clinical Trials Logo

Clinical Trial Summary

Intraoperative flash visual evoked potentials (FVEPs) could monitor visual function during neurosurgery. There are fewer reports comparing the effects of sevoflurane-propofol balanced anesthesia and propofol-based total intravenous anesthesia under comparable bispectral index (BIS) levels on the amplitude and latency of flash visual evoked potentials (FVEPs) for sellar or parasellar tumors resection neurosurgeries.


Clinical Trial Description

The overall incidence rate of sellar tumors is 10-20% of brain tumors. Most of the initial symptoms of this tumor are visual or visual impairment. One of the primary complications of these operations is visual impairment, which directly relates to the quality of patients' life. Flash visual evoked potentials (FVEPs) is an important means of intraoperative visual function evaluation under general anesthesia. Intraoperative visual function damage can be avoided or reduced by observing the changing of FVEPs waves to guide the choice of surgical path. However, since the diversity of anesthetic drugs and methods, there is still a great uncertainty impact on FVEPs, which will interfere with the interpretation and judgment of surgeons and neuroelectrophysiological physicians respect to the changes of FVEPs amplitude and latency, and further affect the operation decision-making. Therefore, it is urgent to establish a perfect anesthesia method for intraoperative monitoring of FVEPs. Although total intravenous anesthesia has been widely accepted for FVEPs monitoring, there are still some limitations, such as the possibility of intraoperative body movement and cough due to the restriction of muscle relaxant use under electrophysiological monitoring, as well as the depression on FVEPs of high maintained dosage under total intravenous anesthesia. The purpose of this study was to investigate the feasibility of FVEPs monitoring during endoscopic sellar tumor resection under combined intravenous anesthesia compared with total intravenous anesthesia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04725032
Study type Interventional
Source Beijing Tiantan Hospital
Contact Ruquan Han, M.D., Ph. D
Phone +861059976660
Email ruquan.han@gmail.com
Status Recruiting
Phase N/A
Start date January 25, 2021
Completion date December 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT04390906 - A Study of Cognitive Changes in Patients Receiving Brain Radiation
Recruiting NCT05298995 - GD2-CAR T Cells for Pediatric Brain Tumours Phase 1
Completed NCT02599142 - Comparing Immobilisation Shells in Cranial Radiotherapy N/A
Not yet recruiting NCT04113278 - Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma
Enrolling by invitation NCT06391294 - Neuronal and Network Mechanisms of Electrocortical Stimulation
Active, not recruiting NCT05832450 - Predictive Model to Calculate the Risk of RBC Transfusion in Elective Brain Tumours Resections (TScoreBTR)
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Recruiting NCT03067467 - Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
Recruiting NCT04468919 - Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit N/A
Recruiting NCT04742231 - Handheld Dynamometer During Awake Craniotomy Pilot N/A
Recruiting NCT03542409 - Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas N/A
Active, not recruiting NCT04165941 - Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma Phase 1
Completed NCT03731455 - WISE Cortical Strip for Intraoperative Neurophysiological Monitoring N/A
Suspended NCT05169944 - Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Phase 1